Rgenta Will Present RGT-61159 Data in October
The clinical-stage firm plans to showcase Phase 1a/b trial results for its MYB splicing modulator at the upcoming ESMO Congress.
Updated on Oct. 13, 2026 in Cancer
Rgenta Therapeutics will present clinical data for its oral MYB splicing modulator, RGT-61159, at the ESMO Congress 2026. The presentation will feature findings from an ongoing Phase 1a/b trial focused on patients with adenoid cystic carcinoma.
Why it matters
Adenoid cystic carcinoma is a rare malignancy, with the MYB oncogene overactivated in over 90% of cases. New therapeutic options are needed for the estimated 200,000 people living with this disease worldwide.
Clinical data will be presented for the oral MYB splicing modulator RGT-61159, which inhibits the production of oncogenic MYB protein. This compound addresses a cancer type that is the second most common malignancy arising in the salivary gland.
The players
Rgenta Therapeutics
This is a clinical-stage biotechnology company based in Woburn, Massachusetts that focuses on developing small-molecule RNA-modulating medicines.
The details
Rgenta Therapeutics is a clinical-stage biotechnology company testing RGT-61159 as a targeted therapy for adenoid cystic carcinoma. The company will formally share these insights during a poster presentation at the medical event in Madrid.
Timeline
October 19, 2026: Full abstract available for public viewing.
October 23, 2026: Full poster available for public viewing.
October 23-27, 2026: ESMO Congress 2026 occurs in Madrid.
October 26, 2026: Poster presentation at 12:00-12:45 p.m. CET.
The Big Picture
This presentation follows a pattern set by the ESMO Congress 2026 where biopharmaceutical firms debut new clinical trial findings. The event serves as a major global forum for the dissemination of oncology research and the advancement of cancer therapeutics.
This study provides a look at a potential future treatment option for those diagnosed with adenoid cystic carcinoma. While the drug is not yet available, clinical trials are the essential pathway toward determining future medical accessibility and treatment standards.
The takeaway
Patients and providers should monitor updates from the trial to understand how targeted MYB modulation may fit into the future of salivary gland cancer treatment. Ongoing clinical investigation remains the primary way to determine if this therapy will become a viable medical standard.
Further reading
Learn more about advancements in Cancer research and treatments.
